Mechanisms underlying methamphetamine-induced dopamine transporter complex formation

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 169-174

  Hadlock, Gregory C ^a   Baucum II, Anthony J ^a   King, Jill L ^a   Horner, Kristen A ^a   Cook, Glen A ^a   Gibb, James W ^a   Wilkins, Diana G ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; ETICLOPRIDE; METHAMPHETAMINE; MONOMER; OXIDOPAMINE;

ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; SYNAPTOSOME; TISSUE SPECIFICITY;

ANIMALS; BENZAZEPINES; BLOTTING, WESTERN; DATA INTERPRETATION, STATISTICAL; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; METHAMPHETAMINE; NEOSTRIATUM; NUCLEUS ACCUMBENS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SYMPATHECTOMY, CHEMICAL; SYNAPTOSOMES;

EID: 63849328969     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.145631     Document Type: Article

References (39)

1. Albers DS and Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-1114.
2. Angulo JA, Angulo N, and Yu J (2004) Antagonists of the neuorokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum. Ann N Y Acad Sci 1025:171-180.
3. Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, and Fleckenstein AE (2004) Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neu-rosci 24:3436-3443.
4. Berman SB, Zigmond MJ, and Hastings TG (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 67:593-600.
5. Block ML and Hong JS (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35:1127-1132.
6. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, and Holson RR (1992) The influence of environmental temperature on the transient effects of methamphet-amine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
7. Broening HW, Morford LL, and Vorhees CV (2005) Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56:84 -93.
8. Broening HW, Pu C, and Vorhees CV (1997) Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 27:153-160.
9. Brown P and Molliver ME (2000) Dual serotonin (5-HT) projections to the nucleus accumbens core and shell: relation of the 5-HT transporter to amphetamine-induced neurotoxicity. J Neurosci 20:1952-1963.
10. Brown JM and Yamamoto BK (2003) Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 99:45-53.
11. Cass WA (1997) Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Exp Ther 280:105-113.
12. Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, and Fleckenstein AE (2008) Differential regional effects of methamphetamine on dopamine transport. Eur J Pharmacol 590:105-110.
13. Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ, and Marshall JF (1992) Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphet-amine. Brain Res 598:321-326.
14. Fleckenstein AE, Gibb JW, and Hanson GR (2000) Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406:1-13.
15. Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, and Hanson GR (1997) Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol 334:111-114.
16. Freed C, Revay R, Vaughan RA, Kriek E, Grant S, Uhl GR, and Kuhar MJ (1995) Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 359:340-349.
17. Fumagalli F, Gainetdinov RR, Valenzano KJ, and Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18:4861-4869.
18. Gibb JW, Hanson GR, and Johnson M (1994) Neurochemical mechanisms of toxicity, in Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse (Cho AK and Segal DS eds) pp 269-295, Academic Press, San Diego, CA.
19. Giovanni A, Liang LP, Hastings TG, and Zigmond MJ (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem 64:1819-1825.
20. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, and Sonsalla PK (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152-160.
21. Gulley JM, Doolen S, and Zahniser NR (2002) Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem 83:400-411.
22. Haughey HM, Fleckenstein AE, and Hanson GR (1999) Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem 72:661-668.
23. Huang CL, Huang NK, Shyue SK, and Chern Y (2003) Hydrogen peroxide induces loss of dopamine transporter activity: a calcium-dependent oxidative mechanism. J Neurochem 86:1247-1259.
24. Imam SZ, el-Yazal J, Newport GD, Itzhak Y, Cadet JL, Slikker W Jr, and Ali SF (2001) Methamphetamine-induced dopaminergic neurotoxicity: role of peroxyni-trite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts.AnnNYAcadSci939:366-380.
25. Kokoshka JM, Vaughan RA, Hanson GR, and Fleckenstein AE (1998) Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol 361:269-275.
26. LaVoie MJ, Card JP, and Hastings TG (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187:47-57.
27. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, and Liu F (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J 26:2127-2136.
28. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
29. Mark KA, Soghomonian JJ, and Yamamoto BK (2004) High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 24:11449-11456.
30. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, and Fleckenstein AE (2000) Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther 295:1077-1085.
31. O'Dell SJ, Weihmuller FB, and Marshall JF (1993) Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J Neurochem 60:1792-1799.
32. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, and Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850-6855.
33. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, and Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233:539-544.
34. Schmidt CJ and Gibb JW (1985) Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur J Pharmacol 109:73-80.
35. Smith MP and Cass WA (2007) Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 144: 1057-1066.
36. Sonsalla PK, Nicklas WJ, and Heikkila RE (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243:398-400.
37. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, and Kuhn DM (2004) Metham-phetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1-7.
38. Wagner GC, Lucot JB, Schuster CR, and Seiden LS (1983) Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res 270:285-288.
39. Yamamoto BK and Zhu W (1998) The effects ofmethamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287:107-114.